NL8600137A - Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. - Google Patents
Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. Download PDFInfo
- Publication number
- NL8600137A NL8600137A NL8600137A NL8600137A NL8600137A NL 8600137 A NL8600137 A NL 8600137A NL 8600137 A NL8600137 A NL 8600137A NL 8600137 A NL8600137 A NL 8600137A NL 8600137 A NL8600137 A NL 8600137A
- Authority
- NL
- Netherlands
- Prior art keywords
- formula
- pharmaceutical
- preparation
- administration
- acid addition
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 25
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 claims description 17
- 229960001035 bopindolol Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000002934 diuretic Substances 0.000 claims description 13
- 206010020852 Hypertonia Diseases 0.000 claims description 12
- 229960001523 chlortalidone Drugs 0.000 claims description 12
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 230000001882 diuretic effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 5
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 241001440269 Cutina Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- VONDEAICGOZHRO-UHFFFAOYSA-N 3-(1h-indol-2-yloxy)propan-1-amine Chemical class C1=CC=C2NC(OCCCN)=CC2=C1 VONDEAICGOZHRO-UHFFFAOYSA-N 0.000 description 2
- -1 3-tert-butylamino-2-hydroxypropoxy Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010036086 Polymenorrhoea Diseases 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858502887A GB8502887D0 (en) | 1985-02-05 | 1985-02-05 | Pharmaceutical compositions |
GB8502887 | 1985-02-05 | ||
DE3505740 | 1985-02-20 | ||
DE3505740 | 1985-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL8600137A true NL8600137A (nl) | 1986-09-01 |
Family
ID=25829545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL8600137A NL8600137A (nl) | 1985-02-05 | 1986-01-22 | Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. |
Country Status (15)
Country | Link |
---|---|
AT (1) | AT393960B (fr) |
AU (1) | AU5293286A (fr) |
BE (1) | BE904146A (fr) |
CH (1) | CH667388A5 (fr) |
DK (1) | DK52186A (fr) |
ES (1) | ES8800597A1 (fr) |
FR (1) | FR2576788A1 (fr) |
GB (1) | GB2173399A (fr) |
GR (1) | GR860307B (fr) |
HU (1) | HU196125B (fr) |
IT (1) | IT1203737B (fr) |
LU (1) | LU86290A1 (fr) |
NL (1) | NL8600137A (fr) |
PH (1) | PH23077A (fr) |
PT (1) | PT81953B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2677886B1 (fr) * | 1991-06-18 | 1995-03-31 | Adir | Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale. |
PL193976B1 (pl) | 2002-07-01 | 2007-04-30 | Pliva Krakow | Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid |
DE102004062257A1 (de) * | 2004-12-23 | 2006-07-06 | Merckle Gmbh | Direkt verpresste Indapamid-Tabletten mit verzögerter Wirkstofffreisetzung |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2738568A (en) * | 1953-08-11 | 1956-03-20 | Civitelli Gennaro | Rasp or file |
AT273761B (de) * | 1965-11-13 | 1969-08-25 | Philipp August Sonn | Abziehvorrichtung für Ski-Stahlkanten |
GB1260907A (en) * | 1968-06-07 | 1972-01-19 | Sandoz Ltd | Indole derivatives |
US4139633A (en) * | 1971-06-15 | 1979-02-13 | Ciba-Geigy Corporation | Pharmaceutical preparations for the treatment of hypertonia |
AT336176B (de) * | 1971-12-10 | 1977-04-25 | Sandoz Ag | Verfahren zur herstellung eines pharmazeutischen praparates |
GB1425033A (en) * | 1972-03-10 | 1976-02-18 | Hendrickson A E | Data signal recogniion apparatus |
US3956616A (en) * | 1974-05-06 | 1976-05-11 | Knollenberg Robert G | Method and apparatus for generating a statistical basis |
DE2635209C2 (de) * | 1975-08-15 | 1983-01-27 | Sandoz-Patent-GmbH, 7850 Lörrach | 4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel |
AT341396B (de) * | 1976-03-01 | 1978-02-10 | C O Oberg & Co Ab | Schleifvorrichtung |
DE2638716A1 (de) * | 1976-08-27 | 1978-03-02 | Ici Gmbh | Antihypertensiva |
DE3140432C2 (de) * | 1980-10-13 | 1985-10-10 | Hitachi, Ltd., Tokio/Tokyo | Drehzahlregelschaltung |
US4388320A (en) * | 1981-03-09 | 1983-06-14 | Sandoz Ltd. | 3-Aminopropoxyaryl derivative in the treatment of tremor |
DD205834B1 (de) * | 1982-03-30 | 1985-12-18 | Mansfeld Kombinat W Pieck Veb | Schnellwechseleinrichtung fuer werkzeuge |
FR2529785A1 (fr) * | 1982-07-09 | 1984-01-13 | Adir | Composition pharmaceutique a base d'indapamide et de 8-(3-tertbutylamino 2-hydroxypropoxy)-thiachromanne |
-
1986
- 1986-01-22 NL NL8600137A patent/NL8600137A/nl not_active Application Discontinuation
- 1986-01-22 HU HU86310A patent/HU196125B/hu unknown
- 1986-01-24 CH CH277/86A patent/CH667388A5/de not_active IP Right Cessation
- 1986-01-30 FR FR8601417A patent/FR2576788A1/fr active Pending
- 1986-01-31 BE BE1/011430A patent/BE904146A/fr not_active IP Right Cessation
- 1986-02-03 GB GB08602601A patent/GB2173399A/en not_active Withdrawn
- 1986-02-03 AU AU52932/86A patent/AU5293286A/en not_active Abandoned
- 1986-02-03 PT PT81953A patent/PT81953B/pt unknown
- 1986-02-03 GR GR860307A patent/GR860307B/el unknown
- 1986-02-03 DK DK52186A patent/DK52186A/da not_active Application Discontinuation
- 1986-02-04 PH PH33378A patent/PH23077A/en unknown
- 1986-02-04 LU LU86290A patent/LU86290A1/fr unknown
- 1986-02-04 IT IT47615/86A patent/IT1203737B/it active
- 1986-02-04 ES ES551634A patent/ES8800597A1/es not_active Expired
- 1986-02-04 AT AT0026186A patent/AT393960B/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUT44934A (en) | 1988-05-30 |
ES551634A0 (es) | 1987-11-16 |
GB2173399A (en) | 1986-10-15 |
GR860307B (en) | 1986-05-27 |
HU196125B (en) | 1988-10-28 |
FR2576788A1 (fr) | 1986-08-08 |
DK52186D0 (da) | 1986-02-03 |
PT81953B (en) | 1987-12-21 |
IT1203737B (it) | 1989-02-23 |
PH23077A (en) | 1989-04-10 |
ES8800597A1 (es) | 1987-11-16 |
BE904146A (fr) | 1986-07-31 |
GB8602601D0 (en) | 1986-03-12 |
IT8647615A0 (it) | 1986-02-04 |
ATA26186A (de) | 1991-07-15 |
AT393960B (de) | 1992-01-10 |
AU5293286A (en) | 1986-08-14 |
PT81953A (en) | 1986-03-01 |
CH667388A5 (de) | 1988-10-14 |
DK52186A (da) | 1986-08-06 |
LU86290A1 (fr) | 1986-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU224215B1 (hu) | Késleltetett felszabadulású ranolazinkészítmények | |
US20080312163A1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors | |
US20090118211A1 (en) | Compositions and Methods for Enhancement of Sexual Function | |
US11890261B2 (en) | Composition and method for treating neurological disease | |
RU2286784C2 (ru) | Таблетка, содержащая цетиризин и псевдоэфедрин | |
CN113784717A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 | |
US10500170B2 (en) | Composition and method for treating neurological disease | |
JPH0761923A (ja) | アルツハイマー病治療剤 | |
US11833121B2 (en) | Composition and method for treating neurological disease | |
KR101414814B1 (ko) | 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법 | |
NL8600137A (nl) | Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. | |
US7767227B2 (en) | Galenical form for oral administration with prolonged release of molsidomine | |
EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
JPS61183221A (ja) | 3‐アミノプロポキシインドール類含有医薬組成物 | |
RU2756320C2 (ru) | Фармацевтическая композиция, содержащая бета-блокатор, ингибитор превращающего фермента и гипотензивное средство или нпвс | |
Karpati et al. | Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension | |
AU2012201640B2 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
AU2269495A (en) | Use of isosorbide-5-mononitrate | |
US20130150375A1 (en) | GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) | |
JP2006509789A (ja) | 不安症治療法及び治療薬 | |
MXPA97006492A (en) | Use of isosorb 5-mononitrate | |
BE894110A (fr) | Utilisation de la trazodone dans le traitement des ulceres gastro-intestinaux | |
JPWO2021127308A5 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BT | A notification was added to the application dossier and made available to the public | ||
BA | A request for search or an international-type search has been filed | ||
BB | A search report has been drawn up | ||
BV | The patent application has lapsed | ||
BV | The patent application has lapsed |